What is the difference between CJC-1295 and Ipamorelin?

CJC-1295 is classified as: Growth hormone-releasing hormone (GHRH) analog. Ipamorelin is classified as: Growth hormone secretagogue; ghrelin (GHS-R1a) receptor agonist (pentapeptide). CJC-1295 is not approved for medical use and is prohibited in one or more regulatory or anti-doping frameworks. Ipamorelin is not approved for medical use and is prohibited in one or more regulatory or anti-doping frameworks.

Is CJC-1295 or Ipamorelin approved?

CJC-1295 is not approved for medical use and is prohibited in one or more regulatory or anti-doping frameworks. Ipamorelin is not approved for medical use and is prohibited in one or more regulatory or anti-doping frameworks. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for CJC-1295 and Ipamorelin?

Peptide Science Daily tracks 1 registered clinical trials for CJC-1295 (evidence grade C) and 3 for Ipamorelin (evidence grade C).

Compound comparison

CJC-1295 vs Ipamorelin

This page sets CJC-1295 and Ipamorelin side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: CJC-1295
Growth hormone-releasing hormone (GHRH) analog
Ipamorelin
Growth hormone secretagogue; ghrelin (GHS-R1a) receptor agonist (pentapeptide)
Mechanism: CJC-1295
In plain terms it tells the pituitary gland to release more of the body's own growth hormone.
Ipamorelin
In plain terms it acts like the hunger hormone ghrelin to switch on growth-hormone release.
United States (FDA): CJC-1295
Not approved for any indication and never marketed. FDA placed CJC-1295 in Category 2 (potential significant safety risk) of the interim 503A bulk drug substances list; the nomination was later withdrawn/removed and the Pharmacy Compounding Advisory Committee did not recommend it for the 503A bulks list.
Ipamorelin
Not approved for any indication. FDA removed ipamorelin acetate from Category 2 of the interim 503A bulks list (September 2024) after the nomination was withdrawn and did not add it to the compoundable 503A list; PCAC review did not support inclusion.
European Union (EMA): CJC-1295
No EMA marketing authorization; not an approved medicine in the EU.
Ipamorelin
No EMA marketing authorization; not an approved medicine in the EU.
Australia (TGA): CJC-1295
Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved GHRH analog. Supply for human therapeutic use is restricted (prescription-only class of substance) and no obesity/GH indication is approved.
Ipamorelin
Not on the ARTG; an unapproved growth hormone secretagogue. Supply for human therapeutic use is restricted (prescription-only class) with no approved indication.
WADA: CJC-1295
Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); GHRH analogues including CJC-1295 are explicitly listed.
Ipamorelin
Prohibited at all times under Section S2; growth hormone secretagogues including ipamorelin are explicitly listed.
Evidence grade: CJC-1295
C
Ipamorelin
C
Tracked clinical trials: CJC-1295
1
Ipamorelin
3
Full profile: CJC-1295
CJC-1295 profile
Ipamorelin
Ipamorelin profile

Comparison of CJC-1295 and Ipamorelin by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	CJC-1295	Ipamorelin
Class	Growth hormone-releasing hormone (GHRH) analog	Growth hormone secretagogue; ghrelin (GHS-R1a) receptor agonist (pentapeptide)
Mechanism	In plain terms it tells the pituitary gland to release more of the body's own growth hormone.	In plain terms it acts like the hunger hormone ghrelin to switch on growth-hormone release.
United States (FDA)	Not approved for any indication and never marketed. FDA placed CJC-1295 in Category 2 (potential significant safety risk) of the interim 503A bulk drug substances list; the nomination was later withdrawn/removed and the Pharmacy Compounding Advisory Committee did not recommend it for the 503A bulks list.	Not approved for any indication. FDA removed ipamorelin acetate from Category 2 of the interim 503A bulks list (September 2024) after the nomination was withdrawn and did not add it to the compoundable 503A list; PCAC review did not support inclusion.
European Union (EMA)	No EMA marketing authorization; not an approved medicine in the EU.	No EMA marketing authorization; not an approved medicine in the EU.
Australia (TGA)	Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved GHRH analog. Supply for human therapeutic use is restricted (prescription-only class of substance) and no obesity/GH indication is approved.	Not on the ARTG; an unapproved growth hormone secretagogue. Supply for human therapeutic use is restricted (prescription-only class) with no approved indication.
WADA	Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); GHRH analogues including CJC-1295 are explicitly listed.	Prohibited at all times under Section S2; growth hormone secretagogues including ipamorelin are explicitly listed.
Evidence grade	C	C
Tracked clinical trials	1	3
Full profile	CJC-1295 profile	Ipamorelin profile

Common questions

What is the difference between CJC-1295 and Ipamorelin?: CJC-1295 is classified as: Growth hormone-releasing hormone (GHRH) analog. Ipamorelin is classified as: Growth hormone secretagogue; ghrelin (GHS-R1a) receptor agonist (pentapeptide). CJC-1295 is not approved for medical use and is prohibited in one or more regulatory or anti-doping frameworks. Ipamorelin is not approved for medical use and is prohibited in one or more regulatory or anti-doping frameworks.
Is CJC-1295 or Ipamorelin approved?: CJC-1295 is not approved for medical use and is prohibited in one or more regulatory or anti-doping frameworks. Ipamorelin is not approved for medical use and is prohibited in one or more regulatory or anti-doping frameworks. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for CJC-1295 and Ipamorelin?: Peptide Science Daily tracks 1 registered clinical trials for CJC-1295 (evidence grade C) and 3 for Ipamorelin (evidence grade C).